This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marco Del Governatore Articles by Hasan, T. Search for Related Content PubMed PubMed Citation Articles by Marco Del Governatore, Articles by Hasan, T.

Experimental Photoimmunotherapy of Hepatic Metastases of Colorectal Cancer with a 17.1A Chlorin_e6 Immunoconjugate¹

Wellman Laboratories of Photomedicine, Department of Dermatology [M. D. G., M. R. H., I. R., T. H.], Vincent Memorial Obstetrics and Gynecology Service, Division of Gynecologic Oncology [K. G. M.], and Department of Surgical Oncology [K. T.], Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, and Departments of Pathology and Medicine (Dermatology) [C. R. S.], Duke University Medical Center, Durham, North Carolina 27710

Photoimmunotherapy (using a monoclonal antibody-targeted photosensitizer and red light) may be a strategy to overcome the limitations inherent in photodynamic therapy of liver tumors. The aims of this study were (a) to test the efficacy of selective treatment of hepatic metastases of colorectal cancer in an orthotopic murine xenograft using the murine monoclonal antibody 17.1A conjugated to the photosensitizer chlorin_e6, and (b) to compare the tumor response after the same light dose was delivered at two different fluence rates. Based on previous biodistribution studies that had shown that the photoimmunoconjugate with a polyanionic charge had both a higher absolute tumor chlorin_e6 content and a greater tumor:normal liver ratio than those obtained with a photoimmunoconjugate bearing a polycationic charge, mice were treated 3 h after i.v. injection of the polyanionic 17.1A chlorin_e6 conjugate or unconjugated photosensitizer. Red light was delivered into the liver tumor by an interstitial fiber, and tumor response end points were total tumor weight in the short term and survival in the long term. There was a highly significant reduction (<20% of controls; P = 0.0035) in the weight of the tumors in the mice treated with photoimmunotherapy, and the median survival increased from 62.5 to 102 days (P = 0.015). Photodynamic therapy with free chlorin_e6 produced a smaller decrease in tumor weight and a smaller extension of survival, neither of which were statistically significant. A comparison of photoimmunotherapy with 10 J of light delivered at 30 or 300 mW showed that the higher fluence rate prolonged survival significantly more than the lower fluence rate. This may have been because the high fluence rate gave a contribution of laser-induced hyperthermia to the photodamage. Correlation studies showed that the amount of normal liver remaining at necropsy correlated best with survival. Photoimmunotherapy shows efficacy in destroying liver tumors, and future studies should maximize selectivity to minimize the destruction of normal liver.

This article has been cited by other articles:

				E. O. Serebrovskaya, E. F. Edelweiss, O. A. Stremovskiy, K. A. Lukyanov, D. M. Chudakov, and S. M. Deyev Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein PNAS, June 9, 2009; 106(23): 9221 - 9225. [Abstract] [Full Text] [PDF]

				G. R. Reddy, M. S. Bhojani, P. McConville, J. Moody, B. A. Moffat, D. E. Hall, G. Kim, Y.-E. L. Koo, M. J. Woolliscroft, J. V. Sugai, et al. Vascular Targeted Nanoparticles for Imaging and Treatment of Brain Tumors. Clin. Cancer Res., November 15, 2006; 12(22): 6677 - 6686. [Abstract] [Full Text] [PDF]

				A. Cuschieri In Situ Ablation of Hepatic Tumors Surgical Innovation, March 1, 2001; 8(1): 25 - 41. [Abstract] [PDF]